Victrex had its target stock price cut from $21.48 per share to $21.33 by Bank of America research analysts. The stock has been rated “underperform.” Analysts from the Jefferies Group have said to “hold” on purchasing the company’s stock, while JPMorgan Chase gave it a “neutral” rating.
Victrex works with manufacturing of high performance polymers through its two business units, Invibio Biomaterial Solutions and Victrex Polymer Solutions.
More Articles on Devices:
MAKO Surgical Settles Lawsuit, Acquires Stanmore Robotic Assets
Stryker Releases Spine Screw, Surgical Devices
Sonoma Orthopedic Products Develops Minimally Invasive Technique For Fractures
Victrex works with manufacturing of high performance polymers through its two business units, Invibio Biomaterial Solutions and Victrex Polymer Solutions.
More Articles on Devices:
MAKO Surgical Settles Lawsuit, Acquires Stanmore Robotic Assets
Stryker Releases Spine Screw, Surgical Devices
Sonoma Orthopedic Products Develops Minimally Invasive Technique For Fractures